MGMarta Garzón-Benavides

Marta Garzón-Benavides

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marta Garzón-Benavides has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Limitations of Faecal Calprotectin in Detecting Histological Changes and Persistent Villous Atrophy in Patients With Coeliac Disease on a Gluten‐Free Diet

    by Verónica Segura, Ángela Ruiz‐Carnicer, Ángeles Pizarro, Carmen González‐Naranjo, Jacobo Díaz, Cristóbal Coronel‐Rodríguez, Federico Argüelles‐Arias, Marta Garzón‐Benavides, Carolina Sousa, Isabel Comino

    Faecal calprotectin is used to assess intestinal inflammation, but its role in monitoring mucosal healing in coeliac disease is unclear. This study followed 48 adults with coeliac disease on a gluten‐free diet over 12 months, evaluating faecal calprotectin levels in correlation with anti‐transglutaminase antibodies, gluten‐free diet adherence by dietary questionnaires and histology. Although significant histological lesions (Marsh II–III) decreased from 24% to 10%, faecal calprotectin levels fluctuated without correlation to anti‐transglutaminase, adherence or histological remission, and did not differentiate between lesion grades. Our findings underscore faecal calprotectin's unreliability in monitoring mucosal healing in adults with coeliac disease, highlighting the urgent need for alternative biomarkers.


  • Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply

    by Marta Garzón‐Benavides, Alfonso Rodríguez‐Herrera, Carolina Sousa, Angeles Pizarro‐Moreno

    LINKED CONTENT: This article is linked to Garzón‐Benavides et al papers. To view these articles, visit https://doi.org/10.1111/apt.17417 and https://doi.org/10.1111/apt.17464

  • Open Access

    Evaluation of the Usefulness of an Automatable Immunoassay for Monitoring Celiac Disease by Quantification of Immunogenic Gluten Peptides in Urine

    by Verónica Segura, Ángela Ruiz-Carnicer, Irati Mendía, Marta Garzón-Benavides, Ángeles E. Pizarro, Isabel Comino, Carolina Sousa

    A gluten-free diet (GFD) is currently the only treatment available for patients with celiac disease (CD). However, adherence to a GFD can be challenging because gluten is present in many foods. A lifelong follow-up of patients with CD must be performed to promote adherence to a GFD and to identify the appearance of symptoms and the associated diseases. Therefore, the development of tools to analyze gluten exposure in these patients is important. This study proposes the development of the first automatable ELISA to monitor adherence to a GFD through the quantification of urine gluten immunogenic peptides (u-GIP). Seven healthy volunteers without suspicion of CD and 23 patients with CD were monitored as part of this study to optimize, validate, and apply this assay. Non-interference was found in the urine matrix, and the recovery percentage for spiked samples was 81–101%. The u-GIP was stable for up to 16 days when the samples were stored at different temperatures. Overall, 100% of the patients had detectable u-GIP at diagnosis (range of 0.39–2.14 ng GIP/mL), which reduced to 27% after 12 months on a GFD. Therefore, this highly sensitive immunoassay would allow the analysis of u-GIP from a large battery of samples in clinical laboratories of specialized healthcare centers.


  • Open Access

    Clinical utility of urinary gluten immunogenic peptides in the follow‐up of patients with coeliac disease

    by Marta Garzón‐Benavides, Ángela Ruiz‐Carnicer, Verónica Segura, Blanca Fombuena, Francisco García‐Fernandez, Salvador Sobrino‐Rodriguez, Lourdes Gómez‐Izquierdo, Marco Antonio Montes‐Cano, Raquel Millan‐Domínguez, María del Carmen Rico, et al.

    Summary: Background: Gluten‐free diet (GFD) is the only treatment for patients with coeliac disease (CD)and its compliance should be monitored to avoid cumulative damage.Aims: To analyse gluten exposures of coeliac patients on GFD for at least 24 months using different monitoring tools and its impact on duodenal histology at 12‐month follow‐up and evaluate the interval of determination of urinary gluten immunogenic peptides (u‐GIP) for the monitoring of GFD adherence.Methods: Ninety‐four patients with CD on a GFD for at least 24 months were prospectively included. Symptoms, serology, CDAT questionnaire, and u‐GIP (three samples/visit) were analysed at inclusion, 3, 6, and 12 months. Duodenal biopsy was performed at inclusion and 12 months.Results: At inclusion, 25.8% presented duodenal mucosal damage; at 12 months, this percentage reduced by half. This histological improvement was indicated by a reduction in u‐GIP but did not correlate with the remaining tools. The determination of u‐GIP detected a higher number of transgressions than serology, regardless of histological evolution type. The presence of >4 u‐GIP‐positive samples out of 12 collected during 12 months predicted histological lesion with a specificity of 93%. Most patients (94%) with negative u‐GIP in ≥2 follow‐up visits showed the absence of histological lesions (p < 0.05).Conclusion: This study suggests that the frequency of recurrent gluten exposures, according to serial determination of u‐GIP, could be related to the persistence of villous atrophy and that a more regular follow‐up every 6 months, instead of annually, provides more useful data about the adequate adherence to GFD and mucosal healing.


  • Negative predictive value of the repeated absence of gluten immunogenic peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-up in celiac disease

    by Ángela Ruiz-Carnicer, Marta Garzón-Benavides, Blanca Fombuena, Verónica Segura, Francisco García-Fernández, Salvador Sobrino-Rodríguez, Lourdes Gómez-Izquierdo, Marcos A Montes-Cano, Alfonso Rodríguez-Herrera, Raquel Millán, et al.

    The treatment of celiac disease (CD) is a lifelong gluten-free diet (GFD). The current methods for monitoring GFD conformance, such as a dietary questionnaire or serology tests, may be inaccurate in detecting dietary transgressions, and duodenal biopsies are invasive, expensive, and not a routine monitoring technique. Our aim was to determine the clinical usefulness of urine gluten immunogenic peptides (GIP) as a biomarker monitoring GFD adherence in celiac patients and to evaluate the concordance of the results with the degree of mucosal damage. A prospective observational study was conducted involving 22 de novo CD patients, 77 celiac patients consuming a GFD, and 13 nonceliac subjects. On 3 d of the week, urine samples were collected and the GIP concentrations were tested. Simultaneously, anti-tissue transglutaminase antibodies, questionnaire results, clinical manifestations, and histological findings were analyzed. Approximately 24% (18 of 76) of the celiac patients consuming a GFD exhibited Marsh II-III mucosal damage. Among this population, 94% (17 of 18) had detectable urine GIP; however, between 60% and 80% were asymptomatic and exhibited negative serology and appropriate GFD adherence based on the questionnaire. In contrast, 97% (31 of 32) of the celiac patients without duodenal damage had no detectable GIP. These results demonstrated the high sensitivity (94%) and negative predictive value (97%) of GIP measurements in relation to duodenal biopsy findings. In the de novo CD-diagnosed cohort, 82% (18 of 22) of patients had measurable amounts of GIP in the urine. Determining GIP concentrations in several urine samples may be an especially convenient approach to assess recent gluten exposure in celiac patients and appears to accurately predict the absence of histological lesions. The introduction of GIP testing as an assessment technique for GFD adherence may help in ascertaining dietary compliance and to target the most suitable intervention during follow-up.


  • Clinical and Pathological Characterization of Lynch-Like Syndrome

    by María Dolores Picó, Adela Castillejo, Óscar Murcia, Mar Giner-Calabuig, Miren Alustiza, Ariadna Sánchez, Leticia Moreira, María Pellise, Antoni Castells, Marta Carrillo-Palau, et al.


  • Pancreatobiliary maljunction: association with gallbladder cancer

    by Marta Garzón Benavides, Andrea Núñez Ortiz, Teófilo López Ruiz, Carmen Cepeda Franco, Lourdes Gómez Izquierdo

    Background: Pancreatobiliary maljunction is a rare disease characterized by the junction of the pancreatic and biliary ducts outside of the duodenal wall, which normally results in a large common duct. As a result, there is a greater risk of acute pancreatitis and cancer of the gallbladder and biliary tract. Case report: We present the case of a 43-year-old female diagnosed with a pancreatobiliary maljunction and an associated stenosis of the bile duct, secondary to an episode of acute pancreatitis. She underwent several endoscopic retrograde cholangiopancreatography procedures over the course of three years, without improvement of the stenosis, and therefore a surgical approach was taken. Prior to the surgical intervention, magnetic resonance imaging showed the presence of an 11-mm polyp in the gallbladder. A histological study of the surgical sample identified intramucosal adenocarcinoma over a tubular adenoma of the gallbladder. Discussion: Pancreatobiliary maljunction can be considered as a premalignant entity due to the risk of developing cancer of the biliary tree and gallbladder. Therefore, these patients should undergo a prophylactic intervention, despite being asymptomatic.


  • Clinically relevant bleeding and thrombotic events in non-cirrhotic splanchnic vein thrombosis. Long-term follow up

    by Luis Jara-Palomares, Lucia Marin-Barrera, Alvaro Giraldez-Gallego, Marta Garzon-Benavides, Teresa Elias-Hernández, Juan Manuel Praena-Fernandez, Maria Isabel Asensio-Cruz, Aurora Solier-Lopez, Lionel Suarez-Valdivia, Jose Maria Sanchez-Diaz, et al.


  • Papel del tratamiento endovascular en la isquemia mesentérica crónica

    by A. Pizarro-Moreno, A. Araujo Miguez, M. Garzón Benavides, V. Nacarino